Last reviewed · How we verify
Anti-CD38 Monoclonal Antibody
Anti-CD38 Monoclonal Antibody is a Monoclonal antibody Small molecule drug developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. It is currently in Phase 1 development for Multiple myeloma.
Monoclonal antibody targeting CD38
Monoclonal antibody targeting CD38 Used for Multiple myeloma.
At a glance
| Generic name | Anti-CD38 Monoclonal Antibody |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Drug class | Monoclonal antibody |
| Target | CD38 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
CD38 is a transmembrane glycoprotein involved in the regulation of cell adhesion, migration, and signaling. The anti-CD38 monoclonal antibody is designed to bind to CD38 and modulate its activity.
Approved indications
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD38 Monoclonal Antibody CI brief — competitive landscape report
- Anti-CD38 Monoclonal Antibody updates RSS · CI watch RSS
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Anti-CD38 Monoclonal Antibody
What is Anti-CD38 Monoclonal Antibody?
Anti-CD38 Monoclonal Antibody is a Monoclonal antibody drug developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd., indicated for Multiple myeloma.
How does Anti-CD38 Monoclonal Antibody work?
Monoclonal antibody targeting CD38
What is Anti-CD38 Monoclonal Antibody used for?
Anti-CD38 Monoclonal Antibody is indicated for Multiple myeloma.
Who makes Anti-CD38 Monoclonal Antibody?
Anti-CD38 Monoclonal Antibody is developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (see full Genrix (Shanghai) Biopharmaceutical Co., Ltd. pipeline at /company/genrix-shanghai-biopharmaceutical-co-ltd).
What drug class is Anti-CD38 Monoclonal Antibody in?
Anti-CD38 Monoclonal Antibody belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.
What development phase is Anti-CD38 Monoclonal Antibody in?
Anti-CD38 Monoclonal Antibody is in Phase 1.
What are the side effects of Anti-CD38 Monoclonal Antibody?
Common side effects of Anti-CD38 Monoclonal Antibody include Fatigue, Nausea, Diarrhea.
What does Anti-CD38 Monoclonal Antibody target?
Anti-CD38 Monoclonal Antibody targets CD38 and is a Monoclonal antibody.
Related
- Drug class: All Monoclonal antibody drugs
- Target: All drugs targeting CD38
- Manufacturer: Genrix (Shanghai) Biopharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Compare: Anti-CD38 Monoclonal Antibody vs similar drugs
- Pricing: Anti-CD38 Monoclonal Antibody cost, discount & access